Abstract 3715
Background
The main objective of this project is to develop a mobile application (APP) for monitoring and controlling the management of the therapeutic regime in this group of people, with a view to strengthening communication among patients and health professionals, favoring adherence to therapeutic indications and responding, in a timely manner and in a proactive manner, to the symptoms or complications that may arise associated with the disease, thereby improving the efficacy of the therapy, preventing complications and improving its perception of health and quality of life. In fact, health interventions must transform behavior towards the desired improvement and empowerment of the person, thus facilitating self-management. Its final presentation will be on the form of an APP, which will improve the well-being and quality of life of people with cancer, bringing gains in efficiency and health outcomes, broadening the sense of the adequacy of policies of health. The expected results with the implementation of this APP are: improve and monitor patient adherence to oral and supportive therapies; to prevent, the appearance of complications or symptoms associated with the treatment, through preventive indications of self-care (green alert level); improve patients responses, through self-care uncontrolled complications (yellow alert level); signaling to the patient and health services, uncontrolled symptoms with high severity (red alert level); improve the efficiency of health teams with regard to self-management of the disease and produce and disseminate knowledge in oncology. At this time the project is already at an advanced stage of development. Systematic reviews of the literature were developed to support the interventions included in the APP. The interventions were categorized by the two levels of self-care and were submitted to expert evaluation using the Delphi technique.
Trial design
Systematic reviews of the literature were developed to support the interventions included in the APP. The interventions were categorized by the two levels of self-care and were submitted to expert evaluation using the Delphi technique. The project has already been tested on an initial sample of 40 patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3252 - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Presenter: Fernanda Costa Svedman
Session: Poster Display session 3
Resources:
Abstract
5545 - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Presenter: Jessica Hassel
Session: Poster Display session 3
Resources:
Abstract
5213 - Genomic landscape of primary malignant melanoma of esophagus
Presenter: Jie Dai
Session: Poster Display session 3
Resources:
Abstract
2716 - A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
3550 - ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Presenter: Marcus Butler
Session: Poster Display session 3
Resources:
Abstract
1645 - PRIME002 - Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy
Presenter: Andre Van Der Westhuizen
Session: Poster Display session 3
Resources:
Abstract
4440 - Pembrolizumab (pembro) Plus Lenvatinib (len) for First-Line Treatment of patients (pts) With Advanced Melanoma: Phase 3 LEAP-003 Study
Presenter: Alexander Eggermont
Session: Poster Display session 3
Resources:
Abstract
3454 - Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma
Presenter: Sanne Huijberts
Session: Poster Display session 3
Resources:
Abstract
1832 - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumor activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib).
Presenter: Lu Si
Session: Poster Display session 3
Resources:
Abstract
3996 - A Phase I Clinical Trial Investigating the Therapeutic Cancer Vaccine UV1 in Combination with Pembrolizumab as First-Line Treatment of Patients with Malignant Melanoma
Presenter: Sanjiv Agarwala
Session: Poster Display session 3
Resources:
Abstract